Regulation of the biosynthesis of the macrolide antibiotic spiramycin in Streptomyces ambofaciens.
Fatma Karray, Emmanuelle Darbon, Hoang Chuong Nguyen, Josette Gagnat, Jean-Luc Pernodet
Index: J. Bacteriol. 192(21) , 5813-21, (2010)
Full Text: HTML
Abstract
Streptomyces ambofaciens synthesizes the macrolide antibiotic spiramycin. The biosynthetic gene cluster for spiramycin has been characterized for S. ambofaciens. In addition to the regulatory gene srmR (srm22), previously identified (M. Geistlich et al., Mol. Microbiol. 6:2019-2029, 1992), three putative regulatory genes had been identified by sequence analysis. Gene expression analysis and gene inactivation experiments showed that only one of these three genes, srm40, plays a major role in the regulation of spiramycin biosynthesis. The disruption of srm22 or srm40 eliminated spiramycin production while their overexpression increased spiramycin production. Expression analysis was performed by reverse transcription-PCR (RT-PCR) for all the genes of the cluster in the wild-type strain and in the srm22 (srmR) and srm40 deletion mutants. The results from the expression analysis, together with the ones from the complementation experiments, indicated that Srm22 is required for srm40 expression, Srm40 being a pathway-specific activator that controls most, if not all, of the spiramycin biosynthetic genes.
Related Compounds
Related Articles:
2012-04-01
[J. Pain Symptom Manage. 43(4) , 679-93, (2012)]
Influences of two antibiotic contaminants on the production, release and toxicity of microcystins
2012-01-01
[Ecotoxicol. Environ. Saf. 77 , 79-87, (2012)]
2012-04-01
[Antimicrob. Agents Chemother. 56(4) , 1762-8, (2012)]
Antioxidant responses and degradation of two antibiotic contaminants in Microcystis aeruginosa.
2012-12-01
[Ecotoxicol. Environ. Saf. 86 , 23-30, (2012)]
Pharmacodynamics and pharmacokinetics of spiramycin and their clinical significance.
1998-04-01
[Clin. Pharmacokinet. 34(4) , 303-10, (1998)]